Download This Paper
Preprints with The Lancet is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the FAQs.
A DNA CpG Methylation Signature Based Diagnosis Model for Early Hepatocellular Carcinoma from HBV-Related Liver Disease
36 Pages Posted: 1 Jun 2021
More...Abstract
Background: Aberrant methylation of CpG sites severed as epigenetic marker for building diagnostic, prognostic, and recurrence models for hepatocellular carcinoma (HCC).
Methods: Using Illumina 450K and EPIC Beadchip, we identified 34 CpG sites in PBMC DNA that were differentially methylated in early HCC versus HBV-related liver diseases (HBVLD). We employed multiplex bisulfite sequencing (MBS) based on next-generation sequencing (NGS) to measure methylation of 34 CpG sites in PBMC DNA from 654 patients that were divided into a training set (n = 442), an test set (n = 212). Using training set, we selected and built a six-CpG-scorer (including cg14171514, cg07721852, cg05166871, cg18087306, cg05213896, and cg18772205), applying least absolute shrinkage and selection operator (LASSO) regression. We performed multivariable analyses of four candidate risk predictors (including six-CpG-scorer, age, sex, AFP level), using 20 times imputation of missing data, non-linearly transformed and backwards feature selection with logistic regression. The final model’s regression coefficients were calculated according to “Rubin's Rules”. The diagnostic accuracy of model was internally validated with 10000 bootstrap validation dataset, and then applied to the test set for validation.
Findings: The area under the receiver operating characteristic curve (AUROC) of the model was 0.81(95% CI, 0.77-0.85) and it showed good calibration, decision curve analysis. Using enhanced bootstrap validation, adjusted C-statistics and adjusted brier score was 0.809 and 0.199, respectively. The model also showed AUROC value of 0.84 (95% CI 0.79-0.88) of diagnosis for early HCC in test set.
Interpretation: Our model based six-CpG-scorer was a reliable diagnosis tool for early HCC from HBVLD. The use of MBS method can realize large-scale detection of CpG loci in clinical diagnosis of early HCC, and benefit the majority of patients.
Funding: This project was supported by grants National Key R&D Program of China (2020YFE0202400), Beijing Natural Science Foundation (7202069, 7191004), Capital’s Funds of Health Improvement and Research (CFH2020-1-2182, CFH2020-2-1153) and Beijing Key Laboratory (BZ0373).
Declaration of Interest: The authors declare no conflict of interest.
Ethical Approval: The study was approved by the Institutional Ethics Committee of the Beijing You’An Hospital. All participants signed written informed consents on enrolment.
Keywords: Multiplex bisulfite sequencing; methylation of CpG sites; early HCC; diagnostic model; enhanced bootstrap validation
Suggested Citation: Suggested Citation